232 related articles for article (PubMed ID: 26338274)
1. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Thijssen R; Ter Burg J; van Bochove GG; de Rooij MF; Kuil A; Jansen MH; Kuijpers TW; Baars JW; Virone-Oddos A; Spaargaren M; Egile C; van Oers MH; Eldering E; Kersten MJ; Kater AP
Leukemia; 2016 Feb; 30(2):337-45. PubMed ID: 26338274
[TBL] [Abstract][Full Text] [Related]
2. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Thijssen R; Ter Burg J; Garrick B; van Bochove GG; Brown JR; Fernandes SM; Rodríguez MS; Michot JM; Hallek M; Eichhorst B; Reinhardt HC; Bendell J; Derks IA; van Kampen RJ; Hege K; Kersten MJ; Trowe T; Filvaroff EH; Eldering E; Kater AP
Blood; 2016 Jul; 128(4):574-83. PubMed ID: 27235137
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.
Papadopoulos KP; Egile C; Ruiz-Soto R; Jiang J; Shi W; Bentzien F; Rasco D; Abrisqueta P; Vose JM; Tabernero J
Leuk Lymphoma; 2015 Jun; 56(6):1763-70. PubMed ID: 25300944
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Yu P; Laird AD; Du X; Wu J; Won KA; Yamaguchi K; Hsu PP; Qian F; Jaeger CT; Zhang W; Buhr CA; Shen P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Lee M; Bentzien F; Lam ST; Dale S; Matthews DJ; Lamb P; Foster P
Mol Cancer Ther; 2014 May; 13(5):1078-91. PubMed ID: 24634413
[TBL] [Abstract][Full Text] [Related]
7. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Thijssen R; Ter Burg J; van Bochove GG; de Rooij MF; Kuil A; Jansen MH; Kuijpers TW; Baars JW; Virone-Oddos A; Spaargaren M; Egile C; van Oers MH; Eldering E; Kersten MJ; Kater AP
Leukemia; 2016 Sep; 30(9):1963. PubMed ID: 27600169
[No Abstract] [Full Text] [Related]
8. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
9. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
[TBL] [Abstract][Full Text] [Related]
10. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; Mohile N; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF
Neuro Oncol; 2015 Sep; 17(9):1275-83. PubMed ID: 26019185
[TBL] [Abstract][Full Text] [Related]
12. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Gravina GL; Mancini A; Scarsella L; Colapietro A; Jitariuc A; Vitale F; Marampon F; Ricevuto E; Festuccia C
Tumour Biol; 2016 Jan; 37(1):341-51. PubMed ID: 26219891
[TBL] [Abstract][Full Text] [Related]
15. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Brown JR; Hamadani M; Hayslip J; Janssens A; Wagner-Johnston N; Ottmann O; Arnason J; Tilly H; Millenson M; Offner F; Gabrail NY; Ganguly S; Ailawadhi S; Kasar S; Kater AP; Doorduijn JK; Gao L; Lager JJ; Wu B; Egile C; Kersten MJ
Lancet Haematol; 2018 Apr; 5(4):e170-e180. PubMed ID: 29550382
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
Hock BD; MacPherson SA; McKenzie JL
PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
[TBL] [Abstract][Full Text] [Related]
17. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
Zhang L; Wang Z; Khishignyam T; Chen T; Zhou C; Zhang Z; Jin M; Wang R; Qiu Y; Kong D
Biomed Pharmacother; 2018 Jul; 103():1069-1078. PubMed ID: 29710665
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
19. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
20. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
